Preengraftment syndrome after unrelated cord blood transplant is a strong predictor of acute and chronic graft-versus-host disease

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 11, 2009, Pages 1485-1488

  Frangoul, Haydar ^a   Wang, Li ^a   Harrell Jr , Frank E ^a   Ho, Richard ^a   Domm, Jennifer ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Cord blood transplant; Graft versus host disease; Preengraftment syndrome

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR1 ANTIGEN; MELPHALAN; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ARTICLE; CELL COUNT; CELL NUCLEUS; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; ENGRAFTMENT SYNDROME; FEMALE; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFANT; MALE; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PREDICTION; PRESCHOOL CHILD; RISK ASSESSMENT; RISK REDUCTION; SCHOOL CHILD; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 70350621880     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.07.001     Document Type: Article

References (13)

1. Kishi Y, Kami M, Miyakoshi S, et al. Early immune reaction after reduced-intensity cord-blood transplantation for adult patients. Transplantation. 2005;80:34-40.
2. Lee YH, Lim YJ, Kim JY, et al. Pre-engraftment syndrome in hematopoietic stem cell transplantation. J Korean Med Sci. 2008;23:98-103.
3. Narimatsu H, Terakura S, Matsuo K, et al. Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults. Bone Marrow Transplant. 2007;39:31-39.
4. Patel KJRR, Hawke RM, Abboud M, Heller G, Scaradavou A, BarkerJN. Pre-Engraftment Syndrome (PES): a clinical syndrome after cord blood (CB) transplantation not associated with acute graft-versus-host disease (aGvHD) or transplant-related mortality (TRM). Biol Blood Marrow Transplant. 2009;15:16.
5. Kurtzberg J, Prasad VK, Carter SL, et al. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood. 2008;112: 4318-4327.
6. Martin PL, Carter SL, Kernan NA, et al. Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. Biol Blood Marrow Transplant. 2006;12:184-194.
7. Wall DA, Carter SL, Kernan NA, et al. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience. Biol Blood Marrow Transplant. 2005;11:637-646.
8. Weisdorf DJ, Hurd D, Carter S, et al. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant. 2003;9:512-518.
9. SpitzerTR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27(9):893-898.
10. Nishio N, Yagasaki H, Takahashi Y, et al. Engraftment syndrome following allogeneic hematopoietic stem cell transplantation in children. Pediatr Transplant. 2008.
11. Schmid I, Stachel D, Pagel P, Albert MH. Incidence, predisposing factors, and outcome of engraftment syndrome in pediatric allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant. 2008;14:438-444.
12. Saliba RM, de Lima M, Giralt S, et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood. 2007;109: 2751-2758.
13. Sullivan KM, Deeg HJ, Sanders J, et al. Hyperacute graft-vhost disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood. 1986;67:1172-1175.